Motohiro T, Kawakami A, Aramaki M, Tanaka K, Koga T, Shimada Y, Tomita S, Sakata Y, Fujimoto T, Nishiyama T
Jpn J Antibiot. 1986 Aug;39(8):2009-47.
Newly developed lenampicillin (LAPC) which is a prodrug of ampicillin (ABPC), and ampicillin (as the control) were each administered to 6 healthy male volunteers, aged from 21 to 25 years (mean 22.4 years) and weighing 57-78 kg (mean 67.0 kg) to study the effect of LAPC and ABPC on fecal bacterial flora. Each drug was given orally 3 times daily (after meals) with each dose of 250 mg for five days. Changes of the fecal bacterial flora caused by the antibiotic were investigated by determining fecal bacterial counts on the 3rd day before the treatment, 0 (the start of treatment), 3rd and 5th days (the final day of treatment) during treatment, and 3rd, 5th and 10th days after the treatment. Fecal concentrations of LAPC and the metabolites (ABPC, 2-aminobenzyl penicilloic acid (ABPA) and 5S-ABPA) for the LAPC group and ABPC for the ABPC group were assayed. A single dose of 500 mg of LAPC was administered orally after breakfast to additional 6 healthy male volunteers and concentrations of LAPC, metabolites (ABPC, ABPA and 5S-ABPA) in the entire stool were determined daily for 5 successive days after the administration. Clinical adverse reactions and abnormal laboratory-findings caused by either drug were studied in the 18 volunteers. The results obtained are summarized as follows. In the bacterial flora of the 6 volunteers to whom LAPC was administered (the LAPC group), the number of isolated E. coli showed no tend of decrease. Mean bacterial counts obtained 3 days before the treatment and at the day of the treatment were 10(9) and 10(8) cells/g, respectively. These values were compared to the counts obtained on the 3rd and the 5th days during the treatment and were found to be about 10(2)-folds as high as the latter. The decreased counts observed on the 3rd and the 5th days did not last and counts increased again to similar levels observed before the treatment. Klebsiella sp. was isolated from 1 or 2 samples before the treatment. It was isolated from as many as 5-6 cases with mean bacterial counts of 10(7)-10(11) cells/g during and up to 5 days after the treatment. The frequency of isolation then decreased to 4 cases on the 10th day after the treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
新开发的仑氨西林(LAPC)是氨苄西林(ABPC)的前体药物,将其与氨苄西林(作为对照)分别给予6名年龄在21至25岁(平均22.4岁)、体重57 - 78千克(平均67.0千克)的健康男性志愿者,以研究LAPC和ABPC对粪便细菌菌群的影响。每种药物每日口服3次(餐后),每次剂量250毫克,持续5天。通过在治疗前第3天、0天(治疗开始时)、治疗期间的第3天和第5天(治疗最后一天)以及治疗后第3天、第5天和第10天测定粪便细菌计数,来研究抗生素引起的粪便细菌菌群变化。测定了LAPC组的LAPC及其代谢产物(ABPC、2 - 氨基苄基青霉素酸(ABPA)和5S - ABPA)以及ABPC组的ABPC的粪便浓度。给另外6名健康男性志愿者早餐后口服单剂量500毫克LAPC,并在给药后连续5天每天测定整个粪便中LAPC、代谢产物(ABPC、ABPA和5S - ABPA)的浓度。在这18名志愿者中研究了两种药物引起的临床不良反应和实验室异常结果。所得结果总结如下。在接受LAPC治疗的6名志愿者(LAPC组)的细菌菌群中,分离出的大肠杆菌数量没有减少趋势。治疗前3天和治疗当天获得的平均细菌计数分别为10⁹和10⁸个细胞/克。将这些值与治疗期间第3天和第5天获得的计数进行比较,发现前者比后者高约10²倍。在第3天和第5天观察到的细菌计数下降并未持续,计数再次增加到治疗前观察到的类似水平。治疗前从1或2个样本中分离出克雷伯菌属。在治疗期间及治疗后5天内,从多达5 - 6例样本中分离出该菌,平均细菌计数为10⁷ - 10¹¹个细胞/克。然后在治疗后第10天,分离频率降至4例。(摘要截断于400字)